Teva Pharmaceutical Industries’ (NYSE and TASE: TEVA) shares were up 4% at 7,323 shekels today reported results for the quarter ended September 30, 2024.
Teva’s third quarter earnings per share (EPS) of $0.69, $0.03 better than analyst’s estimate of $0.66. Revenue for the quarter came in at $4.33 billion, up 13% and higher than the consensus estimate of $4.14 billion.
On a non-generally accepted accounting principles (GAAP) basis, gross profit was $2,327 million, an increase of 13% compared to $2,060 million in the third quarter of 2023
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze